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Effectiveness data of an unboosted atazanavir (ATV) with abacavir/lamivudine (ABC/3TC) switch strategy in clinical routine are scant.
We evaluated treatment outcomes of ATV + ABC/3TC in pretreated subjects in the EuroSIDA cohort when started with
undetectable plasma HIV-1 viral load (pVL), performing a time to loss of virological response (TLOVR<50copies/mL) and a snapshot
analysis at 48, 96, and 144 weeks. Virological failure (VF) was deﬁned as conﬁrmed pVL >50copies/mL.
We included 285 subjects, 67% male, with median baseline CD4 530 cells, and 44 months with pVL 50copies/mL. The third
drug in the previous regimen was ritonavir-boosted atazanavir (ATV/r) in 79 (28%), and another ritonavir-boosted protease inhibitor
(PI/r) in 29 (10%). Ninety (32%) had previously failed with a PI. Proportions of people with virological success at 48/96/144 weeks
were 90%/87%/88% (TLOVR) and 74%/67%/59% (snapshot analysis), respectively. The rates of VF were 8%/8%/6%. Rates of
adverse events leading to study discontinuation were 0.4%/1%/2%. The multivariable adjusted analysis showed an associationditor: Victor Asensi.
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Llibre et al. Medicine (2016) 95:40 Medicinebetween VF and nadir CD4+ (hazard ratio [HR] 0.63 [95% conﬁdence interval [CI]: 0.42–0.93] per 100 cells higher), time with pVL
50copies/mL (HR 0.87 [95% CI: 0.79–0.96] per 6 months longer), and previous failure with a PI (HR 2.78 [95% CI: 1.28–6.04]).
Resistance selection at failure was uncommon.
A switch to ATV + ABC/3TC in selected subjects with suppressed viremia was associated with low rates of VF and discontinuation
due to adverse events, even in subjects not receiving ATV/r. The strategy might be considered in those with long-term suppression
and no prior PI failure.
Abbreviations: ABC/3TC = abacavir/lamivudine, ART = antiretroviral therapy, ATV/r = ritonavir-boosted atazanavir, NNRTI =
non-nucleoside reverse transcriptase inhibitor, NRTI = nucleoside analog reverse transcriptase inhibitors, PI/r = ritonavir-boosted
protease inhibitor, pVL = plasma HIV-1 viral load, TDF = tenofovir disoproxil fumarate, VF = virological failure, ZDV = zidovudine.
Keywords: atazanavir, HIV-1, protease inhibitors: abacavir, simpliﬁcation antiretroviral therapy
1. Introduction backbone,[14,17,19,22] with the remaining cases using tenofovirAntiretroviral guidelines recommend switching a suppressive
antiretroviral therapy (ART) in cases of toxicity, pharma-
cokinetic interactions, pregnancy, and for simpliﬁcation
purposes.[1–4] Preferred options in guidelines to replace a
ritonavir-boosted protease inhibitor (PI/r) include unboosted
atazanavir (ATV), a non-nucleoside reverse transcriptase inhibi-
tor (NNRTI), and the integrase inhibitors raltegravir, dolute-
gravir, or elvitegravir/cobicistat, if full activity of the 2 nucleoside
analog reverse transcriptase inhibitors (NRTI) can be guaranteed.
Low-dose ritonavir (or cobicistat) inhibits P450 cytochrome
enzymes (mainly CYP3A4) and drug transporter P-glycoprotein,
and increases the plasma levels of the PI, thus making it possible
to reduce the total daily dose and dosing intervals.[5] However, it
has the potential to cause multiple pharmacokinetic interactions
with drugs that induce, inhibit, or are simply substrates of this
metabolic pathway, and is generally associated with a poorer
lipid proﬁle. PI/r-based regimens are also typically associated
with higher rates of discontinuation due to intolerance and
toxicity as compared with ART regimens based on other drug
classes.[6,7]
ATV is the only PI that can be used without pharmacokinetic
boosting. One randomized clinical trial demonstrated higher
rates of virological failure (VF) with unboosted ATV in
treatment-naïve subjects, although with less hyperbilirubinemia
and a better lipid proﬁle.[8] Therefore, it is not recommended in
treatment naïves.[8,9]
However, in patients with virological suppression, clinical
trials and a meta-analysis have demonstrated the noninferiority
of unboosted ATV and the absence of major protease mutations
in VF with respect to maintenance of ritonavir-boosted
atazanavir (ATV/r), always combined with abacavir/lamivudine
(ABC/3TC).[10–14] The regimen proved beneﬁcial not only in
terms of lower rates of hyperbilirubinemia and improved lipid
proﬁles, but also reduced consistently some inﬂammatory
markers like lipoprotein-associated phospholipase A2 (LA-
PLA2, but not interleukin-6 or high sensitivity C-reactive
protein), considered an independent predictor of coronary heart
disease by making atherosclerotic plaques in coronary vessels
prone to rupture.[15] This improvement could be related to low-
density lipoprotein cholesterol decreases associated with ritona-
vir removal.[16]
The efﬁcacy of ATV combined with 2NRTIs in clinical practice
has been analyzed in several cohorts, where the inclusion of
difﬁcult-to-treat patients (who are usually excluded in clinical
trials) could reveal weaknesses of this regimen.[17–21] Most of the
studies have limitations in their methodological design that make
it impossible to evaluate with certainty its efﬁcacy. In some
studies, ABC/3TC accounted for only 50% of the NRTI2disoproxil fumarate (TDF) or zidovudine (ZDV) combined with
3TC/emtricitabine. TDF is formally advised against in combina-
tion with unboosted ATV owing to the existing pharmacokinetic
interaction.[17,23]
In addition, the toxicity and efﬁcacy proﬁles of ZDV are
signiﬁcantly worse than that of ABC.[24] Some studies included
treatment-naïve patients in the analysis.[20] Others included
patients with detectable plasma HIV-1 viral load (pVL) at
baseline, or had a short follow-up, or a small sample size with a
mix of subjects also treated with ATV/r.[14,19,21,23] Finally, most
studies included patients with unknownHLA-B∗5701 status, and
could have a higher rate of discontinuation due to suspected
abacavir hypersensitivity reactions.
Therefore, there is uncertainty around the efﬁcacy and safety of
unboosted ATV plus ABC/3TC outside the clinical trial setting
when administered under optimal conditions.
2. Methods
We evaluated the treatment outcomes of unboosted ATV (400mg
once daily) + ABC/3TC in antiretroviral experienced subjects in
the EuroSIDA cohort who started this regimen with an
undetectable pVL (<50copies/mL), and previous ABC experi-
ence or assumed previous HLA-B∗5701 testing. If there were
more than one such episodes, only the ﬁrst one was included. All
subjects with at least 1 month of clinical follow-up were included.
We performed a time to loss of virological response (TLOVR
<50copies/mL and 200copies/mL) and an FDA-recommended
snapshot analysis at 48, 96, and 144 weeks (using the FDA
deﬁnitions and recommended analysis plan).[25] In brief the time
windows were deﬁned as follows: 42 to 54 weeks for week 48, 90
to 102 weeks for week 96, and 138 to 160 weeks for week 144.
We used the pVL ﬁrst hierarchy principle, meaning that people
are classiﬁed according to the pVL value (success if pVL 50
copies, failure if pVL >50) if pVL was available in each of the
time windows. If pVL was missing in the time window, then
patient’s history before the beginning of the time window was
examined (e.g., 0–42 weeks for week 48 window). If the subject
discontinued ATV, ABC or 3TC because of adverse events,
failure, or death or if they added any drug with unfavorable
interactions with ATV before the window, they were deﬁned as
failure. Persons who discontinued because of loss to follow-up or
disconnect from care were classiﬁed according to pVL value at
time of last contact. If the person was still receiving unboosted
ATV + ABC/3TC in the time window and pVL was missing, they
were classiﬁed as “data not available.”
VFwas deﬁned as a conﬁrmed pVL>50copies/mL (failure was
deﬁned at the time of the ﬁrst of 2 consecutive values above the
thresholds).
Table 1
Baseline characteristics of the subjects (n=285).
Sex, male, n (%) 191 (67.0)
Mode of HIVtransmission
IDU 76 (26.7)
Male homosexual sex 98 (34.4)
Heterosexual sex 93 (32.6)
Ethnicity
White 249 (87.4)
Asian 5 (1.8)
Black 19 (6.7)
Hepatitis coinfection (hepatitis C virus antibodies
or HBsAg), n (%)
105 (36.8)
Calendar year of switching to atazanavir, median (IQR) 2008 (2006–2010)
Age, y, median (IQR) 46 (41–53)
CD4 count at switching to atazanavir, cells/mm3,
median (IQR)
530 (357–700)
CD4 count nadir, cells/mm3, median (IQR) 168 (70–243)
Plasma HIV-1 RNA at ﬁrst ART initiation, log copies/mL,
median (IQR)
4.7 (4.0–5.2)
Time with plasma HIV-1 RNA 50 copies/mL,
mo, median (IQR)
44 (23–68)
Third (anchor) drug in the previous regimen, n (%)
ATV/r 79 (27.7)
Other PI/r 29 (10.2)
Other 177 (62.1)
Previously failed a protease inhibitor, n (%) 90 (31.6)
ART = antiretroviral therapy, ATV/r = ritonavir-boosted atazanavir, HBsAg = surface antigen of the
hepatitis B virus, IDU = intravenous drug users, IQR = interquartile range, PI/r = ritonavir-boosted
protease inhibitor.
Llibre et al. Medicine (2016) 95:40 www.md-journal.comAmultivariable analysis was done to identify factors associated
with VF by means of a Cox regression model which included a
number of a priori chosen potential confounders: sex, mode of
HIV transmission, calendar year of switching to unboosted ATV
+ ABC/3TC, age, CD4 count at time of switching and nadir CD4,
pVL at time of starting ART, duration of viral suppression on
previous regimen, history of drug exposure, evidence of previous
VF to PI-based ART, bilirubin level at time of switch, and
hepatitis C or B coinfection status. A VF to a prior PI was deﬁnedTable 2
Outcomes of efﬁcacy at 48, 96, and 144 weeks (FDA snapshot analysis
Disposition, n (%)
HIV-RNA 50 copies/mL 2
HIV-RNA >50 copies/mL
∗
No virological data in window
Discontinued due to adverse events†
Discontinued due to other reasons‡
On study but missing pVL in window
Other endpoints, n (%)
Pure virological failurex (OT), threshold 50 copies/mL
Pure virological failurex (OT), threshold 200 copies/mL
Composite failure or stop due to adverse events†
Composite failure or stop due to other reasons‡
Composite failure or stop due to any reason (TLOVR)
Composite failure or stop due to any reason or pVL missing
OT= on treatment analysis, pVL=plasma HIV-1 viral load, TLOVR= time to loss of virological response
∗
Includes patients who changed any component of background therapy to a new drug class or changed b
regimen because of lack of efﬁcacy (perceived or documented) before window, patients who discontinued st
window.
† Includes patients who discontinued because of adverse event or death at any time point from day 1 thro
‡ Other includes withdrew consent, loss to follow-up, pregnancy, physician decision.
x Denominator N=204 persons with pVL in week 48 window, N=184 persons with pVL in week 96 w
3as a single VL >500copies/mL after at least 4 months from
starting a PI and while still receiving the PI.
Follow-up accrued from the date of switching to the unboosted
ATV-based regimen with a pVL 50copies/L (baseline) to the
date of viral rebound or last available pVL. Resistance test results
available from samples tested in the time window of the estimated
date of VF were extracted from the database and aminoacid
sequences compared with that of wild-type HIV strain.
All participating cohorts followed local national guidelines/
regulations regarding patient consent and/or ethical review.3. Results
We included 285 subjects: 191 (67%) male, median age 46
(interquartile range [IQR] 41–53) years; 249 (87%) white;
hepatitis B or C virus coinfection in 105 (37%); median baseline
CD4 at switch 530 cells (IQR 357–700); time with pVL 50
copies/mL 44 (IQR 23–68) months (Table 1). The third or anchor
drug in the baseline regimen before the switch was ATV/r in 79
(27.7%), and another PI/r in 29 (10.2%). Of all people included,
90 (31.6%) had previously failed with a PI in their regimen, a
median 98 months before (IQR 66–121).
The virological response (TLOVR, composite endpoint
including failure or stop for any reason) was 89.8% (95%
conﬁdence interval [CI]: 85.7–93.1) at 48 weeks, 87.4% (95%
CI: 82.9–91.0) at 96 weeks, and 88.4% (95% CI: 84.1–91.9) at
144 weeks (Table 2). The rate of pure VF (conﬁrmed pVL >50
copies/mL) was 7.8%/7.7%/6.2%, respectively. These rates
decreased to 4.3%/3.4%/3.9%, respectively, using the more
common deﬁnition of VF as a conﬁrmed pVL >200copies/mL.
In the snapshot analysis, pVL was 50copies/mL in 74.4%/
67.0%/58.6%, respectively, and >50copies/mL in 6.3%/5.6%/
3.9%, and 0.4%/0.7%/2.1% discontinued due to adverse
events. There was one newly diagnosed myocardial infarction
(0.4%) reported after the switch to the unboosted ATV-based
regimen and during the study period (1.3 per 1000patients/y of
follow-up). Two (0.7%) subjects discontinued the regimen due
to kidney adverse events, as reported by the treating physician.
One of them also showed a single value of estimated glomerularand sensitivity analyses; 285 subjects unless otherwise speciﬁed).
Week 48 Week 96 Week 144
12 (74.4) 191 (67.0) 167 (58.6)
18 (6.3) 16 (5.6) 11 (3.9)
1 (0.4) 2 (0.7) 6 (2.1)
10 (3.5) 18 (6.3) 16 (5.6)
44 (15.4) 58 (20.4) 85 (29.8)
18 (7.8) 16 (7.7) 11 (6.2)
10 (4.3) 7 (3.4) 7 (3.9)
19 (6.7) 18 (6.3) 17 (6.0)
28 (9.8) 34 (11.9) 27 (9.5)
29 (10.2) 36 (12.6) 33 (11.6)
73 (25.6) 94 (33.0) 118 (41.4)
.
ackground components that were not permitted per protocol or changed any background drug in the
udy drug or study before window for lack or loss of efﬁcacy, and patients who are≥50 copies/mL in the
ugh the time window if this resulted in no virological data on treatment during the speciﬁed window.
indow, and N=144 persons with pVL in week 144 window.
2Table 3
Factors associated with virological failure in a multivariable analysis.
Unadjusted HR (95% CI) P Adjusted
∗
HR (95% CI) P
Sex
Female vs male 0.68 (0.31–1.52) 0.351 1.02 (0.36–2.94) 0.965
Mode of HIV transmission
IDU 1.00 1.00
Homosexual contacts 1.72 (0.71–4.15) 0.228 2.06 (0.54–7.91) 0.292
Heterosexual contacts 0.93 (0.34–2.55) 0.881 1.09 (0.28–4.24) 0.905
Hepatitis coinfection
∗
No 1.00 1.00
Yes 0.85 (0.40–1.81) 0.673 1.68 (0.52–5.39) 0.387
Calendar year of switching to ATV
Per more recent 0.87 (0.74–1.02) 0.076 0.94 (0.79–1.14) 0.547
Age
Per 10 y older 0.92 (0.64–1.31) 0.630 1.05 (0.71–1.56) 0.810
CD4 count at switching to ATV
300 vs >300 0.79 (0.36–1.76) 0.570 1.27 (0.51–3.15) 0.601
CD4 count nadir
Per 100 cells higher 0.71 (0.51–0.99) 0.043 0.63 (0.42–0.93) 0.020
Viral load at ﬁrst ART initiation
>100,000 vs 100,000 copies/mL 1.18 (0.49–2.84) 0.714 0.90 (0.34–2.35) 0.828
Time with pVL 50 copies/mL
Per 6 mo longer 0.89 (0.81–0.97) 0.007 0.87 (0.79–0.96) 0.004
Third drug in previous regimen
ATV/r 1.00 1.00
Other PI/r 2.32 (0.71–7.60) 0.165 1.55 (0.42–5.65) 0.507
Other 1.56 (0.63–3.86) 0.333 1.18 (0.45–3.10) 0.741
Previously failed a PI
Yes vs no 2.05 (1.03–4.05) 0.040 2.78 (1.28–6.04) 0.010
ART = antiretroviral therapy, ATV= atazanavir, ATV/r = ritonavir-boosted atazanavir, CI = conﬁdence interval, HR = hazard ratio, IDU = intravenous drug users, PI/r = ritonavir-boosted protease inhibitor,
pVL=plasma HIV-1 RNA.
∗
Hepatitis C antibodies or HBsAG+.
Llibre et al. Medicine (2016) 95:40 Medicineﬁltration rate decrease to <60mL/min/1.73m (CKD-Epi
formula).
There was a high rate of discontinuations due to other reasons
(not related to VF, toxicity, or death), mainly due to physician’s
decision, or with pVL missing values in the window, due to the
observational nature of the data.
In amultivariable analysis (Table 3), we observed an association
between nadir CD4+ count (hazard ratio [HR] 0.63 [95% CI:
0.42–0.93] per 100 cells higher), time with pVL 50copies/mL
before the switch (HR 0.87 [95% CI: 0.79–0.96] per 6 months
longer), and previous failure with a PI (HR 2.78 [95% CI:
1.28–6.04]) with the risk of VF. There was no evidence of an
association with sex, mode of HIV transmission, age, hepatitis
virus coinfection, calendar year of switching to ATV, CD4+ cell
count at time of switching to ATV, pVL at ﬁrst ART initiation, or
third drug used in the previous regimen. Regarding the latter, there
were no differences in VF rates comparing those who were
receiving ATV/r before the switch to unboosted ATV, with those
who were receiving other PI/r, or non-PI-based regimens.
Two (0.7% of all cohort) out of 8 subjects with conﬁrmed VF
and genotyping data available around the date of failure harbored
major protease mutations. One case presented mutations M46I/
V82T (associated with intermediate ATV resistance, together with
M41L/M184I/L210W/T215Y in the reverse transcriptase), and
the other one showed M46L/I54V/V82A/L90M (high-level ATV
resistance, with D67N/K70R/L74V/M184V/K219E in the reverse
transcriptase). However, there were no genotypic test results
available at the time of switching to unboosted ATV in these 2
subjects, and one of them had documented prior failures to a PI-
based regimen. So, we are unable to establish whether the
mutations detected at time of failure were selected while receiving4unboosted ATV +ABC/3TC or if theywere indeed already present
before switching. A third subject harbored an isolated M184V at
failure (no genotypic resistance tests before unboosted ATV
initiation available). No subject selected the key ATV mutations
I50L, I84V or N88S at failure.4. Discussion
In this analysis of data of patients enrolled in a large cohort of
HIV-infected individuals in Europe, a switch to a regimen
including unboosted ATV plus ABC/3TC in subjects with
suppressed viremia was associated with low rates of VF or
discontinuation due to adverse events at 48, 96, and 144 weeks.
Resistance selection at VF was uncommon, particularly in
subjects without previous PI failures. Results were consistent
when either a TLOVR or the new FDA snapshot deﬁnition for
treatment failure was used.
These data are in agreement with those of previous randomized
clinical trials and support the efﬁcacy of the regimen also in
routine clinical practice, even if we used a more strict VF
deﬁnition in our analysis (a threshold of 50copies/mL of HIV-1
RNA) instead of the more commonly used limit of 200copies/
mL.[10–13] VF rates in the real clinical setting are bound to be
higher than those seen in trials. However, using the threshold of
200copies/mL we identiﬁed rates of VF closer to those seen in
clinical trials. The regimen also showed a good safety proﬁle,
supporting previous similar ﬁndings.[19,20] We found no
signiﬁcant differences regarding sex in the multivariable analysis.
In our cohort subjects had previously been treated with
abacavir or had a negative HLA-B∗5701 allele, therefore the risk
of discontinuation due to suspected ABC hypersensitivity
[10,12]
Llibre et al. Medicine (2016) 95:40 www.md-journal.comreactions was likely to be small. Interestingly, nephrolithiasis was
not reported as a cause of ATV discontinuation, although there
were 2 discontinuations due to renal toxicity as reported by the
treating physician.
One-third of the study subjects came from a previous PI/r
strategy. Of note, we found no signiﬁcant differences in the risk of
VF when comparing people who had ATV/r, other PI/r or other
drugs included in their previous regimen. Our data increase our
understanding of the possible consequences in people switching
to an unboosted ATV-based regimen but coming from treatments
not including ATV/r.
The withdrawal of low-dose ritonavir in people treated with
ATV/r has been associated with the reduction of hyperbilir-
ubinemia and improvements in the lipid proﬁle in previous
studies, and has the potential to prevent pharmacokinetic
interactions.[10–12,14,26,27] These concerns are of particular
importance in the HIV-infected population currently in care as
background cardiovascular risk, the proportion of elderly
patients, and those prone to drug-related toxicities are typically
on the rise.[28] In studies where the switch included a change from
TDF to ABC, a signiﬁcant improvement in markers of bone
turnover and kidney tubule dysfunction was also demonstrat-
ed.[12] In contrast, data on the change in inﬂammatory/
cardiovascular markers following a switch to ATV have been
controversial. Although LA-PLA2 values (a surrogate marker for
metabolic syndrome and incident cardiovascular disease) were
shown to decrease signiﬁcantly, biomarkers of cardiovascular
disease, inﬂammation, or thrombogenesis (hsCRP, interleukin-6,
and D-dimer) generally remained stable.[12,15,16,29] Therefore,
there is currently not enough evidence to recommend a switch to
an unboosted ATV-based regimen if the main goal is to try to
reduce patients’ level of inﬂammation.
Nadir CD4+ cell count, baseline pVL at ﬁrst ART initiation,
time with undetectable pVL before the switch, and previous
failures with a PI were independently associated with VF to the
study regimen in our analysis. Our ﬁndings are useful to guide the
selection of patients who might beneﬁt from this switching
strategy.
Hepatitis C virus coinfection was associated with increased
risk of VF in a previous analysis.[19] The interpretation of this
result was that hepatitis coinfection was a marker for disordered
life-style due to intravenous drug use and nonadherence.[30] Our
data do not conﬁrm this association and are consistent with other
studies showing no impact of HCV coinfection on ATV plasma
levels and liver ﬁbrosis.[31]
Our study has a number of limitations. First of all, it is an
observational study and therefore we cannot rule out channeling
in (confounding by indication) and channeling out (reasons for
stopping ATV are not random) biases. Also, there was a high rate
of discontinuations due to reasons unrelated to efﬁcacy and of
people with missing pVL values in the snapshot windows, a
common ﬁnding in observational studies, which could result in
underreporting of toxicity and failure. In addition, this is a single
treatment analysis with no control group as it is difﬁcult to
identify suitable control groups of switching strategies in the
observational setting. It is therefore difﬁcult to put our estimates
of VF into context as the rate of switching in people who did not
switch is counterfactual (e.g., missing data) and unclear which
other estimates could be used as comparator.
On the contrary, strengths of our analysis include the
proportion of female patients, of subjects with hepatitis B or C
coinfection or of intravenous drug use, and with a lower nadir
CD4+ cell count in our study population compared with pivotal5randomized clinical trials evaluating the strategy. Our
analysis also provides further long-term data on the efﬁcacy of
unboosted ATV when used in combination with the optimal
NRTI background of ABC/3TC in subjects who were not treated
with ATV/r—and particularly not treated with PIs—at baseline.
In summary, our analysis of the data of this large prospective
cohort suggests that a switch to unboosted ATV + ABC/3TC
regimen with a pVL 50copies/mL is associated with a low risk
of VF and discontinuation due to adverse events, and conﬁrms
outcome data previously seen in randomized clinical trials. This
risk was smallest in patients with no prior evidence of VF to a PI,
those with a high CD4+ nadir cell count and with long-term viral
suppression. These data may also have interest in resource-
limited countries where all 3 components are available as FDA-
certiﬁed generic or low-cost treatments. Additional work is
needed to further guide the selection of people who are likely to
beneﬁt from this strategy and inform antiretroviral treatment
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